drugset / Trial / NCT05259813
Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL
Phase 1
Withdrawn
Shanghai Ming Ju Biotechnology Co., Ltd.
The First Affiliated Hospital with Nanjing Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I, open-label, single-arm, single center study to assess the safety and efficacy of JWCAR029 in subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Timeline
- Start
- 2022-02-28
- Primary completion
- 2023-01-31
- Completion
- 2025-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Relmacabtagene Autoleucel | Cell therapy | — | — |